Testing effectiveness (Phase 2)Ended earlyNCT03173950
What this trial is testing
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
Who this might be right for
MedulloblastomaEpendymomaPineal Region Tumors+2 more
National Cancer Institute (NCI) 136